The NHS is offering two contracts to pay pharma companies at the start of their research into antibiotics, to promote the development of new antimicrobials.
List view / Grid view
Filter the results
Following a record level of data collated by WHO, the organisation has emphasised that new antibiotics need to be developed to tackle the rise of global antimicrobial resistance.
Recarbrio (imipenem-cilastatin and relebactam) was approved for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
While membrane filtration is often straightforward, some sample types can be challenging. These include difficult-to-filter viscous oils, water-in-oil emulsions and fatty base ointments as well as samples containing substances that inhibit microbial growth.
The company announced the voluntary recall is due to low, out of specification dissolution test results in specific batches of its tetracycline products.
A study of both city and rural water sources identified antimicrobials at every site and suggests the contamination could be causing the emergence of treatment-resistant microbes.
Pharmaceutical manufacturing can lead to the contamination of water ways and supply. Here, the ultimate effects from pharma’s role in environmental pollution is examined.
During the manufacture of antibiotics, residues can contaminate the environment through wastewater, leading to antimicrobial resistance. However, a new government initiative in India aims to prevent this by regulating effluent.
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) was devised to create transformative regimens for TB treatment, irrespective of drug resistance status.
Researchers at Aston University and Birmingham Children’s Hospital, UK, have discovered a highly effective three-drug approach to treat Mycobacterium abscessus (M. abscessus), a notoriously drug-resistant pathogen that affects up to 13 percent of cystic fibrosis (CF) patients in the UK.
Research has developed bandages which change colour and release antibiotics and/or reactive oxygen species in response to an infected wound which could curb the spread of antibiotic resistance.
The World Health Organization (WHO) has released new reports which state that a lack of innovation in new antibiotic development is undermining efforts to combat drug-resistant infections.
A new report has said the majority of the active ingredients used in pharmaceuticals have never been evaluated for environmental risks.
The US FDA has granted approval for the marketing authorisation of Talicia, intended to treat adults with H. pylori infection.
The UK government will invest £3.5 million to help develop new antibitoic treatments for gonorrhoea and make them available to low- and middle-income countries.